These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 17269937

  • 1. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
    Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR.
    J Thromb Haemost; 2007 Feb; 5(2):352-61. PubMed ID: 17269937
    [Abstract] [Full Text] [Related]

  • 2. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, Wilcox DA, Shi Q.
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [Abstract] [Full Text] [Related]

  • 3. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
    Shi Q, Schroeder JA, Kuether EL, Montgomery RR.
    J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
    [Abstract] [Full Text] [Related]

  • 4. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
    Chen J, Schroeder JA, Luo X, Montgomery RR, Shi Q.
    J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
    [Abstract] [Full Text] [Related]

  • 5. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y, Luo X, Schroeder JA, Chen J, Baumgartner CK, Hu J, Shi Q.
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [Abstract] [Full Text] [Related]

  • 6. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
    Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, Montgomery RR.
    Blood; 2008 Oct 01; 112(7):2713-21. PubMed ID: 18495954
    [Abstract] [Full Text] [Related]

  • 7. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
    Shi Q, Kuether EL, Chen Y, Schroeder JA, Fahs SA, Montgomery RR.
    Blood; 2014 Jan 16; 123(3):395-403. PubMed ID: 24269957
    [Abstract] [Full Text] [Related]

  • 8. Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice.
    Ramezani A, Zweier-Renn LA, Hawley RG.
    Thromb Haemost; 2011 Apr 16; 105(4):676-87. PubMed ID: 21264447
    [Abstract] [Full Text] [Related]

  • 9. In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.
    Schroeder JA, Chen Y, Fang J, Wilcox DA, Shi Q.
    J Thromb Haemost; 2014 Aug 16; 12(8):1283-93. PubMed ID: 24931217
    [Abstract] [Full Text] [Related]

  • 10. Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells.
    Jing W, Baumgartner CK, Xue F, Schroeder JA, Shi Q.
    J Thromb Haemost; 2023 Mar 16; 21(3):488-498. PubMed ID: 36696197
    [Abstract] [Full Text] [Related]

  • 11. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
    Van Damme A, Chuah MK, Dell'accio F, De Bari C, Luyten F, Collen D, VandenDriessche T.
    Haemophilia; 2003 Jan 16; 9(1):94-103. PubMed ID: 12558785
    [Abstract] [Full Text] [Related]

  • 12. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
    Wang X, Shin SC, Chiang AF, Khan I, Pan D, Rawlings DJ, Miao CH.
    Mol Ther; 2015 Apr 16; 23(4):617-26. PubMed ID: 25655313
    [Abstract] [Full Text] [Related]

  • 13. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
    Chen Y, Schroeder JA, Chen J, Luo X, Baumgartner CK, Montgomery RR, Hu J, Shi Q.
    Blood; 2016 Mar 10; 127(10):1346-54. PubMed ID: 26668132
    [Abstract] [Full Text] [Related]

  • 14. Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.
    Baumgartner CK, Zhang G, Kuether EL, Weiler H, Shi Q, Montgomery RR.
    J Thromb Haemost; 2015 Dec 10; 13(12):2210-9. PubMed ID: 26453193
    [Abstract] [Full Text] [Related]

  • 15. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Hebbel RP, Galipeau J, Hough C, Lillicrap D.
    Stem Cells; 2007 Oct 10; 25(10):2660-9. PubMed ID: 17615271
    [Abstract] [Full Text] [Related]

  • 16. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
    Kootstra NA, Matsumura R, Verma IM.
    Mol Ther; 2003 May 10; 7(5 Pt 1):623-31. PubMed ID: 12718905
    [Abstract] [Full Text] [Related]

  • 17. Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.
    Gao C, Schroeder JA, Xue F, Jing W, Cai Y, Scheck A, Subramaniam S, Rao S, Weiler H, Czechowicz A, Shi Q.
    Blood Adv; 2019 Sep 24; 3(18):2700-2711. PubMed ID: 31515232
    [Abstract] [Full Text] [Related]

  • 18. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
    Doering CB, Denning G, Shields JE, Fine EJ, Parker ET, Srivastava A, Lollar P, Spencer HT.
    Hum Gene Ther; 2018 Oct 24; 29(10):1183-1201. PubMed ID: 30160169
    [Abstract] [Full Text] [Related]

  • 19. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
    Tiede A, Eder M, von Depka M, Battmer K, Luther S, Kiem HP, Ganser A, Scherr M.
    Gene Ther; 2003 Oct 24; 10(22):1917-25. PubMed ID: 14502221
    [Abstract] [Full Text] [Related]

  • 20. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
    Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR.
    J Clin Invest; 2006 Jul 24; 116(7):1974-82. PubMed ID: 16823491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.